Skip to main content
970 search results for:

ADA Scientific Sessions 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. Open Access 01-11-2019 | Obesity | ReviewPaper

    Major Advances and Discoveries in Diabetes - 2019 in Review

    Last February, I received an email from the American Diabetes Association’s (ADA) Scientific Sessions Planning Committee inviting me to participate as a speaker at the 79th annual meeting. I have always enjoyed attending the ADA Scientific

  2. 20-07-2023 | Obesity | News | Article

    Oral semaglutide induces meaningful bodyweight reductions in people without type 2 diabetes

    The study findings were also presented at the 83rd ADA Scientific Sessions in San Diego, California, USA. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2023 Springer Healthcare Ltd, part of the Springer Nature Group Lancet 2023; doi:10.1016/S0140-6736(23)01185-6

  3. 19-07-2023 | Type 2 Diabetes | News | Article

    Triple agonist shows promise for both glycemic and weight control

    The findings, which were simultaneously presented at the 83rd ADA Scientific Sessions in San Diego, California, USA, confirm those of the 12-week phase 1 study and “support phase 3 clinical development” of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide (GLP)-1, and glucagon receptor agonist, the researchers comment.

  4. 17-07-2023 | Type 2 Diabetes | News | Article

    Orforglipron superior to dulaglutide for HbA1c reduction in type 2 diabetes

    The study findings were also presented at the 83rd ADA Scientific Sessions in San Diego, California, USA. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2023 Springer Healthcare Ltd, part of the Springer Nature Group Lancet 2023; doi: 10.1016/ S0140-6736(23)01302-8 Lancet 2023; doi: 10.1016/S0140-6736(23)01201-1

  5. 14-07-2023 | Type 2 Diabetes | News | Article

    Cagrilintide plus semaglutide shows dual benefit in type 2 diabetes

    “These data support further investigation of CagriSema in this population in longer and larger phase 3 studies,” suggest Frias and team, who also reported the data at the 83rd ADA Scientific Sessions in San Diego, California, USA.

  6. 20-03-2024 | Events

    Abstracts

  7. 06-07-2023 | Obesity | News | Article

    Phase 2 trial shows positive weight loss outcomes with oral orforglipron

    The study, reported in The New England Journal of Medicine and presented at the 83rd ADA Scientific Sessions in San Diego, California, USA, included 272 adults with obesity or with overweight plus at least one weight-related coexisting condition, but no diabetes.

  8. 30-06-2023 | Type 2 Diabetes | News | Article

    ‘Substantial’ bodyweight reductions with tirzepatide in people with type 2 diabetes and obesity

    The study, which was simultaneously presented at the 83rd ADA Scientific Sessions in San Diego, California, USA, included 938 people with type 2 diabetes (51% women, 76% White, 60% Hispanic or Latino) aged an average of 54 years.

  9. 09-01-2024 | Abstract

    51st ESCP symposium on clinical pharmacy 31 October–02 November 2023, Aberdeen, Scotland

    Innovations in clinical pharmacy practice, education and research
  10. 23-10-2023 | Diabetic Neuropathy | ReviewPaper

    Effects of exercises and manual therapy on nerve conduction studies of lower limb in patients with diabetes and diabetic peripheral neuropathy: A systematic review

    Diabetic peripheral neuropathy (DPN) is the most common debilitating complication of diabetes. The prevalence of DPN is 21.3 to 34.5% [ 1 ], and it increases with age and duration of diabetes [ 2 ]. During the course of the disease, 40–59% of …

  11. 28-06-2023 | Type 2 Diabetes | News | Article

    ONWARDS 1: Weekly insulin icodec outperforms daily insulin glargine U100 in type 2 diabetes

    The phase 3a, open-label trial, which was simultaneously presented at the 83rd ADA Scientific Sessions in San Diego, California, USA, looked at the long-term effects of insulin icodec versus insulin glargine U100 over a 78-week period, comprising a 52-week main phase and a 26-week extension phase.

  12. Open Access 01-09-2023 | Juvenile Rheumatoid Arthritis | Abstract

    Proceedings of the 29th European Paediatric Rheumatology Congress

  13. 04-09-2023 | Insulins | Abstract

    59 th EASD Annual Meeting of the European Association for the Study of Diabetes

    Hamburg, Germany, 2 - 6 October 2023

    1 …

  14. Open Access 01-12-2024 | Gestational Diabetes | OriginalPaper

    Physical activity during pregnancy and the risk of gestational diabetes mellitus: a systematic review and dose–response meta-analysis

    Gestational diabetes mellitus (GDM) is one of the most prevalent pregnancy complications. Since the World Health Organization (WHO) identified GDM as an individual type of diabetes in 1997, GDM has attracted considerable attention in the fields of …

  15. Open Access 01-12-2024 | Acupuncture | OriginalPaper

    Electroacupuncture efficacy in diabetic polyneuropathy: Study protocol for a double-blinded randomized controlled multicenter clinical trial

    T2DM is a public health problem, according to the International Diabetes Federation (IDF) it was estimated that 537 million people had diabetes in 2021 [ 1 , 2 ], which occurs nearly in an 80% in low-income and middle-income countries [ 2 ], such …

  16. 01-01-2023 | Alzheimer's Disease | Abstract

    16th Clinical Trials on Alzheimer’s Disease (CTAD) Boston, MA (USA) October 24–27, 2023: Posters

  17. Open Access 20-09-2023 | Diabetes Prevention | ReviewPaper

    Workplace Interventions for Type 2 Diabetes Mellitus Prevention—an Umbrella Review

    The International Diabetes Federation estimated in its 2021 report that 537 million adults aged 20–79 were diagnosed with diabetes worldwide, and forecasted the increase to 643 million in 2030, and to 743 million in 2045. The most common type of …

  18. Open Access 01-12-2024 | ReviewPaper

    Developing a community-led rare disease ELSI research agenda

    Community engagement throughout all stages of the research process is recognized to enhance study relevance and quality [ 1 – 3 ]. Reflecting this, community engagement in research is increasingly encouraged and even required by funders [ 4 ]. In …

  19. Open Access 14-05-2024 | Stroke | Online First

    Factor XI Inhibitors: perspectives in primary and secondary prevention of ischemic stroke

    Stroke is one of the most common causes of mortality and disability worldwide. Antithrombotic therapy represents the mainstay in primary and secondary prevention, both in cardioembolic and non-cardioembolic stroke. Particularly, direct oral …

  20. Open Access 01-09-2022 | Juvenile Rheumatoid Arthritis | Abstract

    Proceedings of the 28th European Paediatric Rheumatology Congress (PReS 2022)

    Prague, Czech Republic. 20-23 September 2022

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.